VRCA Verrica Pharmaceuticals
- 8.940
- -0.210-2.30%
Verrica Pharmaceuticals News
Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $16 Price Target
Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $16 price target.
Analysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT) and Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals Amends Global Trial and Equity Terms
Express News | Verrica Pharmaceuticals Announces Amendment To License Agreement With Torii Pharmaceutical To Kointly Conduct Phase 3 Trial Of YCANTH
Express News | Verrica Pharmaceuticals Inc - Global Pivotal Phase 3 Clinical Trial Expected to Begin in 1(St) Half of 2025
Express News | Verrica Pharmaceuticals Inc - Funding Structure Is Expected to Have a Minimal Impact on Verrica's Cash Position
Express News | Verrica Pharmaceuticals Inc - Amendment Should Benefit Both Parties From a Cost and Time to Market Standpoint
Express News | Verrica Pharmaceuticals Inc - Global Pivotal Phase 3 Clinical Trial Would Be Conducted Jointly by Verrica and Torii Pharmaceutical
Express News | Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement With Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth® for the Treatment of Common Warts
Express News | Verrica Pharmaceuticals Shares Are Trading Higher Are Trading Higher Possibly Amid Strength in High-short Interest Stocks After Retail Trader 'Roaring Kitty' Returned to Social Media. Also, Needham and HC Wainwright Raised Their Respective Price...
Express News | Verrica Pharmaceuticals Inc : Jefferies Raises Target Price to $12 From $10
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Roth MKM cu
Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating
Verrica Pharmaceuticals (VRCA) has an average rating of buy and price targets ranging from $8 to $22, according to analysts polled by Capital IQ. Price: 9.45, Change: -0.11, Percent Change: -1.15
Insiders the Biggest Winners as Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA) Market Cap Rises to US$406m
Key Insights Verrica Pharmaceuticals' significant insider ownership suggests inherent interests in company's expansion The top 2 shareholders own 53% of the company Institutions own 17% of Verric
Express News | Verrica Pharmaceuticals Inc : H.c. Wainwright Raises Target Price to $14 From $13
Verrica Pharmaceuticals Is Maintained at Buy by Needham
Verrica Pharmaceuticals Is Maintained at Buy by Needham
Verrica Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 69.31% Needham $8 → $16 Maintains Buy 04/10/2024 -15.34% Needham → $8 Reiterates Buy → Buy 03/0
Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Express News | Verrica Pharmaceuticals Inc : Needham Raises Target Price to $16 From $8
Stocks With More Than 10% Short Interest - Finviz Screener
Analysis
Price Target
No Data
